The mission of the Cancer Research and Treatment Fund is to provide the resources for state of the art research that leads to effective treatments for cancer.

Since its formation in 1968, CR&T has focused on finding the most efficient ways to bring the lab closer to the patient’s bedside in the ongoing search for a cure for cancer. Through our support of skilled physician-scientists, the Fund has helped advance the treatment of blood malignancies as well as of more common cancers such as those of the prostate, breast, lung and colon.

This reflects the important role that hematological research has played in the development of new therapies. Because blood cancer cannot be excised by surgery, hematologists have had to seek solutions that are principally biological and pharmacological.

Combined with the recent breakthroughs in gene mapping, today’s pioneering CR&T associates are instrumental in the development of new molecule-targeting agents that focus on the genetic makeup of the cancer itself, leaving unaffected the surrounding tissue, thus minimizing the side affects of more dramatic chemical treatments. This new targeted therapy has produced a host of drugs that give hope to cancer patients.

The goal of CR&T is to bridge the gap quickly and safely between the laboratory and the bedside, bringing promising treatments to the patient. Here is where an organization like CR&T can be a valuable resource. The Cancer Research and Treatment Fund has no layers of redundant personnel and no endless committees. It can move swiftly and decisively in the direction that long experience suggests will lead to the best payoff in terms of better patient care.

CR&T’s independence and small size are keys to its continued success. We will continue to work smarter and faster to earn the continued loyalty of friends and benefactors who believe in the its winning combination of research and care-giving.